Brokerages Set OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) PT at $5.67

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) have been given a consensus rating of “Hold” by the five analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $5.6667.

Several brokerages have commented on OKYO. HC Wainwright dropped their price objective on OKYO Pharma from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Monday, July 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OKYO Pharma in a research note on Friday, July 17th.

OKYO Pharma Stock Up 4.7%

OKYO opened at $1.55 on Monday. OKYO Pharma has a fifty-two week low of $1.34 and a fifty-two week high of $3.35. The company has a fifty day moving average of $1.58 and a two-hundred day moving average of $1.74.

Hedge Funds Weigh In On OKYO Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC acquired a new position in shares of OKYO Pharma in the third quarter worth $31,000. Renaissance Technologies LLC raised its holdings in shares of OKYO Pharma by 235.0% in the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock valued at $286,000 after purchasing an additional 96,800 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of OKYO Pharma during the 4th quarter worth $36,000. Institutional investors and hedge funds own 2.97% of the company’s stock.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.